Adminstering rosiglitazone protected against cardiac hypertrophy and decreased sEH levels in that study, suggesting crosstalk between PPAR and sEH pathways that may be relevant in diabetes [20]. The gene discussed is EPHX2; the disease is cardiac hypertrophy.